Waters SJ - Search Results

1

Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent.

Herzig MC, Trevino AV, Liang H, Salinas R, Waters SJ, MacDonald JR, Woynarowska BA, Woynarowski JM. Herzig MC, et al. Among authors: waters sj. Biochem Pharmacol. 2003 Feb 15;65(4):503-13. doi: 10.1016/s0006-2952(02)01552-6. Biochem Pharmacol. 2003. PMID: 12566077

2

Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells.

Woynarowski JM, Woynarowska BA, Trevino AV, Salinas R, Herman TS, Waters SJ, Macdonald JR. Woynarowski JM, et al. Among authors: waters sj. Cancer Biol Ther. 2004 Nov;3(11):1137-42; discussion 1143-4. doi: 10.4161/cbt.3.11.1216. Epub 2004 Nov 9. Cancer Biol Ther. 2004. PMID: 15467441 Free article.

3

Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells.

Liang H, Salinas RA, Leal BZ, Kosakowska-Cholody T, Michejda CJ, Waters SJ, Herman TS, Woynarowski JM, Woynarowska BA. Liang H, et al. Among authors: waters sj. Mol Cancer Ther. 2004 Nov;3(11):1385-96. Mol Cancer Ther. 2004. PMID: 15542777

4

Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases.

Wang W, Waters SJ, MacDonald JR, Roth C, Shentu S, Freeman J, Von Hoff DD, Miller AR. Wang W, et al. Among authors: waters sj. Anticancer Res. 2002 Mar-Apr;22(2A):559-64. Anticancer Res. 2002. PMID: 12014623

5

Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells.

Wang W, Waters SJ, MacDonald JR, Von Hoff DD, Strodel WE, Miller AR. Wang W, et al. Among authors: waters sj. Anticancer Res. 2001 May-Jun;21(3B):1789-94. Anticancer Res. 2001. PMID: 11497260

6

Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.

Van Laar ES, Weitman S, MacDonald JR, Waters SJ. Van Laar ES, et al. Among authors: waters sj. Prostate. 2004 Apr 1;59(1):22-32. doi: 10.1002/pros.10351. Prostate. 2004. PMID: 14991863

7

MGI 114: augmentation of antitumor activity when combined with topotecan.

Weitman S, Barrera H, Moore R, Gonzalez C, Marty J, Hilsenbeck S, MacDonald JR, Waters SJ, Von Hoff D. Weitman S, et al. Among authors: waters sj. J Pediatr Hematol Oncol. 2000 Jul-Aug;22(4):306-14. doi: 10.1097/00043426-200007000-00006. J Pediatr Hematol Oncol. 2000. PMID: 10959900

8

Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo.

Van Laar ES, Roth S, Weitman S, MacDonald JR, Waters SJ. Van Laar ES, et al. Among authors: waters sj. Anticancer Res. 2004 Jan-Feb;24(1):59-65. Anticancer Res. 2004. PMID: 15015576 Free article.

9

Structure-activity studies of antitumor agent irofulven (hydroxymethylacylfulvene) and analogues.

McMorris TC, Yu J, Lira R, Dawe R, MacDonald JR, Waters SJ, Estes LA, Kelner MJ. McMorris TC, et al. Among authors: waters sj. J Org Chem. 2001 Sep 7;66(18):6158-63. doi: 10.1021/jo010458z. J Org Chem. 2001. PMID: 11529745

10

Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.

van Laar ES, Izbicka E, Weitman S, Medina-Gundrum L, Macdonald JR, Waters SJ. van Laar ES, et al. Among authors: waters sj. Int J Gynecol Cancer. 2004 Sep-Oct;14(5):824-31. doi: 10.1111/j.1048-891X.2004.014515.x. Int J Gynecol Cancer. 2004. PMID: 15361190

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters